A multicentre, prospective, randomised controlled study of efficacy and safety of decitabine combination with low dose CAG in patients with myelodysplastic syndrome.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2016
At a glance
- Drugs Aclarubicin (Primary) ; Cytarabine (Primary) ; Decitabine (Primary) ; Granulocyte colony-stimulating factors (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 21 May 2012 Planned end date 15 Oct 2015 added as reported by Chinese Clinical Trial Register.
- 25 Nov 2011 New trial record